留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞癌患者肝动脉化疗栓塞术后外周血长链非编码RNA TINCR水平与Th1/Th2平衡及预后的相关性分析

柏涛 王静丽 胡旭东 夏冰 程海林 王娟

柏涛, 王静丽, 胡旭东, 等. 肝细胞癌患者肝动脉化疗栓塞术后外周血长链非编码RNA TINCR水平与Th1/Th2平衡及预后的相关性分析[J]. 临床肝胆病杂志, 2021, 37(1): 79-83. DOI: 10.3969/j.issn.1001-5256.2021.01.016
引用本文: 柏涛, 王静丽, 胡旭东, 等. 肝细胞癌患者肝动脉化疗栓塞术后外周血长链非编码RNA TINCR水平与Th1/Th2平衡及预后的相关性分析[J]. 临床肝胆病杂志, 2021, 37(1): 79-83. DOI: 10.3969/j.issn.1001-5256.2021.01.016
BAI T, WANG JL, HU XD, et al. Association of the expression level of the long non-coding RNA TINCR in peripheral blood with Th1/Th2 balance and prognosis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(1): 79-83. DOI: 10.3969/j.issn.1001-5256.2021.01.016
Citation: BAI T, WANG JL, HU XD, et al. Association of the expression level of the long non-coding RNA TINCR in peripheral blood with Th1/Th2 balance and prognosis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(1): 79-83. DOI: 10.3969/j.issn.1001-5256.2021.01.016

肝细胞癌患者肝动脉化疗栓塞术后外周血长链非编码RNA TINCR水平与Th1/Th2平衡及预后的相关性分析

DOI: 10.3969/j.issn.1001-5256.2021.01.016
基金项目: 

武汉市卫生与计划生育委员会科研课题 WX12D24

详细信息
    作者简介:

    柏涛(1981—),男,主治医师,主要从事肝病的临床治疗及基础研究

    通讯作者:

    柏涛,baitao811027@163.com

  • 利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突,特此声明。
  • 作者贡献声明:柏涛、王静丽负责课题设计,资料分析,撰写论文;夏冰、程海林、王娟参与收集数据,修改论文;胡旭东负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R735.7

Association of the expression level of the long non-coding RNA TINCR in peripheral blood with Th1/Th2 balance and prognosis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

  • 摘要:   目的  探讨分析外周血长链非编码RNA(lncRNA) TINCR表达水平与肝细胞癌(HCC)患者行肝动脉化疗栓塞术(TACE)术后辅助性T淋巴细胞1(Th1)/Th2平衡及预后的相关性。  方法  回顾性选取2015年3月—2017年3月在湖北省武汉市金银潭医院行TACE治疗的HCC患者85例,并随机抽取在本院体检的健康志愿者30例作为对照组。检测HCC患者TACE完成后7 d及对照组外周血lncRNA TINCR表达情况、Th1/Th2细胞因子表达情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验,等级资料组间比较采用Kruskal-Wallis H检验。lncRNA TINCR相对表达量与Th1/Th2细胞因子的相关性采用Spearman相关性分析。lncRNA TINCR相对表达量对生存情况的影响采用Kaplan-Meier生存曲线分析,生存曲线比较采用log-rank检验。  结果  HCC组患者外周血lncRN TINCR相对表达量(1.784±0.429)高于对照组(0.926±0.263),差异有统计学意义(t=10.277,P<0.05)。lncRNA TINCR相对表达与HCC患者血管侵犯、肿瘤大小、肿瘤分期及血清AFP水平有关(t值分别为3.958、4.499、3.361、4.949,P值分别为<0.001、<0.001、0.001、<0.001)。HCC组患者血清IFNγ、IL-2水平明显低于对照组[(13.48±5.20) pg/ml vs (27.49±7.21) pg/ml、(21.89±6.45) pg/ml vs (32.05±7.89) pg/ml,t值分别为11.408、6.986,P值均<0.05],而IL-4、IL-10水平明显高于对照组[(13.73±3.35) pg/ml vs (9.36±2.73) pg/ml、(12.75±2.74) pg/ml vs (8.93±2.16) pg/ml,t值分别为6.426、6.909,P值均<0.05]。HCC患者外周血lncRNA TINCR相对表达量与血清IFNγ、IL-2水平呈负相关(r值分别为-3.164、-3.270,P值均<0.001),与患者血清IL-4、IL-10呈正相关(r值分别为2.963、3.044,P值分别为0.007、<0.001)。以lncRNA TINCR相对表达量≥1.700作为高表达,85例HCC患者中lncRNA TINCR高表达患者47例,低表达患者38例。log-rank检验结果显示,lncRNA TINCR低表达患者生存情况明显优于高表达患者(χ2=4.182, P<0.05)。  结论  HCC患者行TACE后外周血lncRNA TINCR表达明显高于健康人群,lncRNA TINCR表达与患者病理特征及Th1/Th2免疫平衡有密切联系,可作为患者生存预后的潜在预测指标之一。
  • 图  1  lncRNA TINCR相对表达量与患者预后关系

    表  1  lncRNA TINCR相对表达量与HCC患者病理特征分析

    项目 例数 lncRNA TINCR相对表达量 统计值 P
    性别 t=1.148 0.254
      男 46 1.895±0.318
      女 39 1.972±0.296
    年龄 t=0.798 0.427
      ≥50岁 49 1.964±0.304
      <50岁 36 1.912±0.287
    Child-Pugh分级 Z=0.864 0.433
      A级 26 1.974±0.412
      B级 53 2.061±0.397
      C级 6 1.875±0.332
    血管侵犯 t=3.958 <0.001
      有 64 2.108±0.227
      无 21 1.864±0.295
    肿瘤大小 t=4.499 <0.001
      >5 cm 51 2.175±0.304
      ≤5 cm 34 1.903±0.218
    临床分期 t=3.361 0.001
      Ⅱ期 44 1.764±0.275
      Ⅲ期 41 1.974±0.301
    肝炎病史 t=0.293 0.770
      有 67 1.922±0.341
      无 18 1.896±0.307
    血清AFP t=4.949 <0.001
      <400 ng/ml 33 1.816±0.197
      ≥400 ng/ml 52 2.095±0.283
    下载: 导出CSV

    表  2  两组受试者Th1/Th2细胞因子水平比较

    组别 例数 IFNγ(pg/ml) IL-2(pg/ml) IL-4(pg/ml) IL-10(pg/ml)
    HCC组 85 13.48±5.20 21.89±6.45 13.73±3.35 12.75±2.74
    对照组 30 27.49±7.21 32.05±7.89 9.36±2.73 8.93±2.16
    t 11.408 6.986 6.426 6.909
    P <0.05 <0.05 <0.05 <0.05
    下载: 导出CSV
  • [1] LI XC, WANG HW, LI CX. Present situation and prospect of comprehensive treatment of hepatocellular carcinoma[J]. Chin J Dig Surg, 2018, 17(5): 433-436. (in Chinese) DOI: 10.3760/cma.j.issn.1673-9752.2018.05.004

    李相成, 王宏伟, 李长贤. 肝癌综合治疗的现状与展望[J]. 中华消化外科杂志, 2018, 17(5): 433-436. DOI: 10.3760/cma.j.issn.1673-9752.2018.05.004
    [2] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
    [3] CHEN Z, YAO L, LIU Y, et al. LncTIC1 interacts with β-catenin to drive liver TIC self-renewal and liver tumorigenesis[J]. Cancer Lett, 2018, 430: 88-96. DOI: 10.1016/j.canlet.2018.05.023
    [4] HUANG LN, LENG KM, XU Y, et al. Expressions and roles of long non-coding RNA ROR in tumors[J]. Mod Med J, 2017, 45(12): 1865-1870.(in Chinese) DOI: 10.3969/j.1671-7562.2017.12.041

    黄立宁, 冷开明, 徐艺, 等. 长链非编码RNA ROR在肿瘤中的表达和作用[J]. 现代医学, 2017, 45(12): 1865-1870. DOI: 10.3969/j.1671-7562.2017.12.041
    [5] HE T, ZHANG L, KONG Y, et al. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis[J]. Int J Oncol, 2017, 51(6): 1722-1730. DOI: 10.3892/ijo.2017.4175
    [6] CHEN Z, LIU Y, YAO L, et al. The long noncoding RNA lncZic2 drives the self-renewal of liver tumor-initiating cells via the protein kinase C substrates MARCKS and MARCKSL1[J]. J Biol Chem, 2018, 293(21): 7982-7992. DOI: 10.1074/jbc.RA117.001321
    [7] TANG GJ, TIAN Y, WANG JT, et al. Advances in long non-coding RNA in chemotherapeutic resistance of hepatocellular carcinoma[J]. Med J Chin PLA, 2020, 45(5): 547-553. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202005016.htm

    唐贵菊, 田塬, 王继婷, 等. 长链非编码RNA在肝癌化疗耐药中的研究进展[J]. 解放军医学杂志, 2020, 45(5): 547-553. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202005016.htm
    [8] LIU T, YANG H, FAN W, et al. Mechanisms of MAFG dysregulation in cholestatic liver injury and development of liver cancer[J]. Gastroenterology, 2018, 155(2): 557-571. e14. DOI: 10.1053/j.gastro.2018.04.032
    [9] CAI C, YANG L, TANG Y, et al. Prediction of overall survival in gastric cancer using a nine-lncRNA[J]. DNA Cell Biol, 2019, 38(9): 1005-1012. DOI: 10.1089/dna.2019.4832
    [10] LIU HR, LIU XL, YIN BB, et al. Association between SALL4 and lncRNA in human hepatocellular carcinoma[J]. Chin J Cancer Prev Treat, 2017, 24(21): 1518-1522, 1529.(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201721007.htm

    刘海荣, 刘晓琳, 殷蓓蓓, 等. 原发性肝细胞肝癌组织SALL4与LncRNA表达相关性研究[J]. 中华肿瘤防治杂志, 2017, 24(21): 1518-1522, 1529. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201721007.htm
    [11] WU J, LI JT, WEI HL, et al. Advances in the role of microRNA in the intervention of malignant transformation of precancerous lesions of the liver by regulating the activation of hepatic stellate cells[J]. J Clin Hepatol, 2020, 36(7): 1650-1654. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.07.045

    吴杰, 李京涛, 魏海梁, 等. microRNA调控肝星状细胞活化干预肝癌癌前病变的研究进展[J]. 临床肝胆病杂志, 2020, 36(7): 1650-1654. DOI: 10.3969/j.issn.1001-5256.2020.07.045
    [12] PANG Y, KARTSONAKI C, TURNBULL I, et al. Diabetes, plasma glucose, and incidence of fatty liver, cirrhosis, and liver cancer: A prospective study of 0.5 million people[J]. Hepatology, 2018, 68(4): 1308-1318. DOI: 10.1002/hep.30083
    [13] ZHAI JJ, DU XR, LI CX. Effect of lncRNA HOTAIR on the radiosensitivity of HCCLM3 cells[J]. Natl Med J China, 2020, 100(18): 1419-1425.(in Chinese) DOI: 10.3760/cma.j.cn112137-20190928-02130

    翟金俊, 杜贤荣, 李彩霞. lncRNA HOTAIR对肝癌细胞HCCLM3放射敏感性的影响[J]. 中华医学杂志, 2020, 100(18): 1419-1425. DOI: 10.3760/cma.j.cn112137-20190928-02130
    [14] FANG T, LV H, LV G, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer[J]. Nat Commun, 2018, 9(1): 191. DOI: 10.1038/s41467-017-02583-0
    [15] MALKI A, EL-SHARKAWY A, EL SYAED M, et al. Antitumor activities of the novel isosteviol derivative 10C against liver cancer[J]. Anticancer Res, 2017, 37(4): 1591-1601. DOI: 10.21873/anticanres.11489
    [16] YANG PJ, LI X, DOU KF. Research progress of long non coding RNA in transplantation immunity[J]. Ogran Transplantation, 2018, 9(2): 91-96. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201802001.htm

    杨佩军, 李霄, 窦科峰. 长链非编码RNA在移植免疫中的研究进展[J]. 器官移植, 2018, 9(2): 91-96. https://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201802001.htm
    [17] CHEN SS, CHEN X, JIANG QY, et al. Expression and prognostic significance of long non-coding RNA CCAT1 in hepatocellular carcinoma[J]. J Med Res, 2018, 47(9): 86-89.(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ201809022.htm

    陈思思, 陈霞, 蒋琼英, 等. 长链非编码RNA CCAT1在肝细胞肝癌中的表达及预后意义[J]. 医学研究杂志, 2018, 47(9): 86-89. https://www.cnki.com.cn/Article/CJFDTOTAL-YXYZ201809022.htm
    [18] ZHANG S, ZHU J, WU XB, et al. Expressions of LncRNA TINCR and ANRIL in liver cancer tissues and their relationships with the prognosis of the patients[J]. J Trop Med, 2019, 19(1): 55-59. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ201901014.htm

    张帅, 朱佳, 吴相柏, 等. 肝癌组织LncRNA TINCR和ANRIL表达水平及其与患者预后的关系[J]. 热带医学杂志, 2019, 19(1): 55-59. https://www.cnki.com.cn/Article/CJFDTOTAL-RDYZ201901014.htm
    [19] ZHOU W, ZHANG S, LI J, et al. lncRNA TINCR participates in ALA-PDT-induced apoptosis and autophagy in cutaneous squamous cell carcinoma[J]. J Cell Biochem, 2019, 120(8): 13893-13902. DOI: 10.1002/jcb.28662
    [20] HOU A, ZHANG Y, ZHENG Y, et al. LncRNA terminal differentiation-induced ncRNA (TINCR) sponges miR-302 to upregulate cyclin D1 in cervical squamous cell carcinoma (CSCC)[J]. Hum Cell, 2019, 32(4): 515-521. DOI: 10.1007/s13577-019-00268-y
    [21] HE X, LI L, FANG Y, et al. In vivo imaging of leucine aminopeptidase activity in drug-induced liver injury and liver cancer via a near-infrared fluorescent probe[J]. Chem Sci, 2017, 8(5): 3479-3483. DOI: 10.1039/C6SC05712H
  • 加载中
图(1) / 表(2)
计量
  • 文章访问数:  74
  • HTML全文浏览量:  9
  • PDF下载量:  35
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-30
  • 修回日期:  2020-08-21
  • 刊出日期:  2021-01-18
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回